Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NeoGenomics, Inc.
Deal-making and financing activities are on the rise for liquid biopsy diagnostic products in 2021 despite questions remaining around whether the technology can unseat standard-of-care biomarker and imaging tests.
PerkinElmer will add chemiluminescence products in endocrinology, autoimmunity and diagnostics to its portfolio with the planned buyout of Immunodiagnostics.
Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
- Contract Research Organization-CRO
Laboratory Testing Services
- Anatomical Pathology
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
- Clarient, Inc.
- Genoptix, Inc.
- Genoptix Medical Laboratory
- Inviata Ltd.
- NeoGenomics Laboratories